John Law, MD
Family Medicine · Farragut, TNNPI 1740259761
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 63.0% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $21,070 and has fallen 90.9% since, to $1,926 in 2025. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 899 payments — averaging $38.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$22K
- AbbVie$2K
- Novo Nordisk$1K
- Pfizer$1K
- Lilly USA, LLC$743
- AstraZeneca$680
- plus $7K from 54 others
What the payments were for
- Speaking & faculty fees$16,22047%
- Travel & lodging$4,22712%
- Food & beverage$14,31341%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$12,073
- Truvada$7,516
- ENROUTE Transcarotid Stent$147
- ENROUTE Transcarotid Neuroprotection System$147
- AIRSUPRA$128
- BREZTRI$128
- FARXIGA$128
- Biktarvy$121
- ZEPBOUND$120
- XARELTO$104
How this compares
$34,860 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 78 | $119,221 |
| DescovyEmtricitabine/Tenofov Alafenam | 28 | $61,435 |
| EliquisApixaban | 66 | $60,368 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $42,666 |
| OzempicSemaglutide | 17 | $22,429 |
| GlyxambiEmpagliflozin/Linagliptin | 25 | $22,296 |
| FarxigaDapagliflozin Propanediol | 25 | $21,014 |
| LinzessLinaclotide | 17 | $16,700 |
| VraylarCariprazine Hcl | 11 | $14,893 |
| Repatha SureclickEvolocumab | 13 | $9,340 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 23 | $8,086 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,881 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,625 |
| Testosterone | 12 | $2,191 |
| Testosterone Cypionate | 25 | $1,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $743 | $119,22178 claims |
| GileadDescovy, Biktarvy | $21,946 | $104,10139 claims |
| PfizerEliquis | $1,155 | $60,36866 claims |
| AbbVieLinzess, Vraylar | $1,672 | $31,59228 claims |
| Novo NordiskOzempic | $1,331 | $22,42917 claims |
| Boehringer IngelheimGlyxambi | $618 | $22,29625 claims |
| AstraZenecaFarxiga | $680 | $21,01425 claims |
| GSKBreo Ellipta, Shingrix | $377 | $11,50638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Farragut
- Richard MattisonFarragut$31K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.